The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
“We're really striving to compress manufacturing timelines and to make sure that patients receive the cells as fast as possible and in the most reliable way possible... There's definitely an unmet need for patients we serve patients in the fourth or fifth line of multiple myeloma, they really have no options. Sometimes they progress very fast as they wait for the CAR T cells, so this definitely addresses a critical need for patients.”
Novartis’s PHE885 is an autologous BCMA-directed chimeric antigen receptor (CAR) T-cell therapy developed using the company’s T-Charge platform for the potential treatment of multiple myeloma. The therapy is being evaluated in a currently recruiting phase 1 study (NCT05172596).
Data from the phase 1 study were presented at the Onco Cell Therapy Summit (OCTS) USA 2022, held June 29-30 in Boston, Massachusetts by Serena De Vita, MD, PhD, senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research.
CGTLive spoke with De Vita to learn more about the manufacturing advantages of the T-Charge platform and the data seen so far with PHE885. She discussed positive efficacy and safety data as well as another candidate developed with the T-Charge platform, YTB323.